Croissy-Beaubourg, December 10, 2019, 5.45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, announces today that it has strengthened its international presence by signing…
This exclusive deal with the French diagnostic specialist facilitates the first launch of PredictImmune’s prognostic tests in mainland Europe; and enables IBD patients in France, Belgium, Luxembourg and Switzerland to benefit from early prognosis. Cambridge,…
Continued improvement in operating income Extraordinary income from non-recurring instrumentation sales generating investment capacity, to be reinvested in key strategic markets Cash position: €3.2 million, sufficient for upcoming investments Croissy-Beaubourg, September 24, 2019, 5:45pm CEST – THERADIAG (ISIN:…